Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hydroxychloroquine sulphate - tablet, film coated - 200 mg - hydroxychloroquine sulphate 200.0 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - hydroxychloroquine sulphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - amlodipine besilate; irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - salmonella typhi vi polysaccharide, quantity: 0.025 mg - injection, solution - excipient ingredients: monobasic sodium phosphate; phenol; water for injections; sodium chloride; dibasic sodium phosphate dihydrate - for the active immunisation against typhoid fever, in subjects over 5 years of age. indications as at 9 october 2000: typhim vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 200mg - tablet - 200 mg - active: tiaprofenic acid 200mg